Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity, Common Stock Purchase Warrants, and Noncontrolling Interest

v3.20.2
Stockholders' Equity, Common Stock Purchase Warrants, and Noncontrolling Interest
6 Months Ended
Jun. 30, 2020
Equity [Abstract]  
Stockholders' Equity, Common Stock Purchase Warrants, and Noncontrolling Interest

Note 13 — Stockholders’ Equity, Common Stock Purchase Warrants, and Noncontrolling Interest

 

As of June 30, 2020, a total of 17,250 common stock purchase warrants were issued and outstanding, with a weighted average exercise price of $1.68 per share of common stock of the Company; and, as of June 30, 2019, a total of 18,449 common stock purchase warrants were issued and outstanding with a weighted average exercise price of $1.57 per share of common stock of the Company. During the six months ended June 30, 2020, 1,199 Series S Warrants were exercised for cash proceeds of $12, resulting in the issuance of a corresponding number of shares of the Company’s common stock.

 

Subsequent to June 30, 2020, at the annual meeting of stockholders held on July 24, 2020the Company’s stockholders approved an increase of authorized shares of common stock of the Company by 50.0 million shares, from 100.0 million shares to 150.0 million shares.

 

The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity for the periods indicated is as follows:

 

    Six Months
Ended
June 30, 2020
    Year Ended
December 31, 2019
 
NCI - equity (deficit) - beginning of period   $ (814 )   $ (162 )
Minority Interest investment in Solys Diagnostics Inc           889  
Minority Interest share subscription receivable - Solys Diagnostics Inc.           (889 )
Minority Interest Lucid Diagnostics Inc. 2018 Equity Plan stock option exercise     5        
Net loss attributable to NCI - Lucid Diagnostics Inc.     (640 )     (801 )
Net loss attributable to NCI - Solys Diagnostics Inc.     (62 )     (10 )
Stock-based compensation expense - Lucid Diagnostics Inc. 2018 Equity Plan     26       159  
NCI - equity (deficit) - end of period   $ (1,485 )   $ (814 )